Future perspectives for biological response modifiers: a viewpoint.
D000276:Adjuvants, Immunologic / Q000494:pharmacology / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000951:Antigens, Neoplasm / Q000276:immunology; D000970:Antineoplastic Agents / Q000494:pharmacology; D001500:BCG Vaccine / Q000627:therapeutic use; D001688:Biological Products / Q000627:therapeutic use*; D002454:Cell Differentiation / Q000187:drug effects; D017358:Cell Wall Skeleton; D003131:Combined Modality Therapy; D016207:Cytokines; D006023:Glycoproteins / Q000627:therapeutic use; D006133:Growth Substances / Q000627:therapeutic use; D006801:Humans; D007114:Immunization; D007116:Immunization, Passive; D007167:Immunotherapy; D007372:Interferons / Q000627:therapeutic use; D007694:Killer Cells, Natural / Q000276:immunology; D008222:Lymphokines / Q000627:therapeutic use; D008262:Macrophage Activation; D009088:Mucoproteins / Q000627:therapeutic use; D009369:Neoplasms / Q000628:therapy*; D009389:Neovascularization, Pathologic; D010844:Picibanil / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha
D000276:Adjuvants, Immunologic; D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D001500:BCG Vaccine; D001688:Biological Products; D017358:Cell Wall Skeleton; D016207:Cytokines; D006023:Glycoproteins; D006133:Growth Substances; D008222:Lymphokines; D009088:Mucoproteins; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; C044553:cell wall skeleton, Nocardia; D010844:Picibanil; D007372:Interferons